L3VLUP
ProSign in

ARWR in the 13F filings

Arrowhead Pharmaceuticals In · CUSIP 04280A100

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
latest of these filings; the earliest 14 Nov 2023
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 3 listed it in both
Shares listed
2,304,418
combined, among listed positions
Reported value
$62m
combined, at the quarter end

Managers listing ARWR in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Rokos Capital Management LLP1,675,921$45m0.33%Held014 Nov 2023 (the filing on sec.gov)
Woodline Partners LP468,497$13m0.15%Added+372,53014 Nov 2023 (the filing on sec.gov)
Hudson Bay Capital Management LP160,000$4.3munder 0.1%Added+47,50014 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (1)

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2024 to 9 in Q2 2026

Tracked managers listing it, at least.

035810201820192020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
ARWR by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20171$476kn.a.n.a.
Q3 20171$618kn.a.n.a.
Q4 20171$1.2mn.a.n.a.
Q1 20183$4.6mn.a.n.a.
Q2 20182$2.5mn.a.n.a.
Q3 20181$181kn.a.n.a.
Q4 20181$19mn.a.n.a.
Q1 20192$37mn.a.n.a.
Q2 20192$54mn.a.n.a.
Q3 20191$18mn.a.n.a.
Q4 20197$302mn.a.n.a.
Q1 20206$69mn.a.n.a.
Q2 20205$260mn.a.n.a.
Q3 20204$221mn.a.n.a.
Q4 20205$372mn.a.n.a.
Q1 20215$336mn.a.n.a.
Q2 20216$253mn.a.n.a.
Q3 20215$133mn.a.n.a.
Q4 20213$249mn.a.n.a.
Q1 20225$161mn.a.n.a.
Q2 20223$122mn.a.n.a.
Q3 20223$118mn.a.n.a.
Q4 20222$121mn.a.n.a.
Q1 20234$69mn.a.n.a.
Q2 20234$67mn.a.n.a.
Q3 20233$62mn.a.n.a.
Q4 20234$87m31
Q1 20244$67m03
Q2 20244$61m22
Q3 20243$29m22
Q4 20243$40m21
Q1 20252$7.4m02
Q2 20255$56m40
Q3 202510$232m63
Q4 20256$275m1615
Q1 20268$257m1911
Q2 20269$969m1616

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

ARWR and LLY →ARWR and JNJ →ARWR and VRTX →Choose a stock to compare with ARWR →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own ARWR, latest filings →Back to the 13F Explorer →